General Information
|
|
Files
|
Kythera Biopharmaceuticals, Inc. (FKA: Aestherx, Inc.) |
|
|
|
Woodland Hills, CA
http://www.kytherabiopharma.com
Keith Leonard
CEO, Board Member
6303 Owensmouth Avenue Tenth Floor
Woodland Hills, CA 91367
818-936-2627
Legal Counsel: Wilson Sonsini Goodrich & Rosati
|
|
Provides medical product research and development. The Company is focused on the development and commercialization of innovative prescription products for the rapidly expanding aesthetic and medical dermatology markets.
Geographic Region: Southern California
Industry Sector: Biotechnology
|
|
|
|
Investors
|
Altitude Life Science Management, LLC |
ARCH Venture Partners |
JAFCO Co., Ltd. |
Prospect Venture Partners (FKA: Prospect Management LLC) |
Undisclosed Non Venture Firm |
Undisclosed Venture Firm |
Versant Ventures |
Wilson, Sonsini, Goodrich & Rosati (AKA: WS Investments) |
|
Investments - Tabular Analysis
| |
05/19/2008 |
05/09/2006 |
09/16/2005 |
Round Number |
3 |
2 |
1 |
Total Investment |
30.00 |
20.00 |
1.00 |
Stage |
Expansion |
Startup/Early Stage |
Startup/Early Stage |
Investors |
Altitude Life Science Management, LLC
ARCH Venture Partners
ARCH Venture Partners
JAFCO Co., Ltd.
Prospect Venture Partners (FKA: Prospect Management LLC)
Undisclosed Non Venture Firm
Undisclosed Non Venture Firm
Undisclosed Venture Firm
Versant Ventures
Wilson, Sonsini, Goodrich & Rosati (AKA: WS Investments)
|
ARCH Venture Partners
Prospect Venture Partners (FKA: Prospect Management LLC)
Versant Ventures
|
Versant Ventures
|
Deal Terms - Tabular Analysis
| |
05/09/2006 |
05/15/2008 |
|
Post-Money Valuation
(best-estimate based on regulatory filings)
|
$ 58,029,797
(© 2008 VC Experts.com, Inc.) |
$ 137,897,001
(© 2008 VC Experts.com, Inc.) |
|
Round of Financing
|
Series B |
Series C |
Natl: 28% |
Reg: 29% |
Natl: 20% |
Reg: 21% |
Type of Preferred Stock
|
Conventional Convertible |
Conventional Convertible |
Natl: 32% |
Reg: 36% |
Natl: 32% |
Reg: 36% |
Capped Participating Preferred
|
|
|
| |
|
|
|
Liquidation Preference for the Current Round
|
Pari Passu |
Senior |
Natl: 32% |
Reg: 31% |
Natl: 37% |
Reg: 38% |
Multiple of the Liquidation Preference: 1x; 2x; 3x; > 3x.
|
0 - 1x |
0 - 1x |
Natl: 92% |
Reg: 93% |
Natl: 92% |
Reg: 93% |
Round Direction
|
Up Round |
Up Round |
Natl: 46% |
Reg: 50% |
Natl: 46% |
Reg: 50% |
Anti-Dilution Protection
|
Weighted Average |
Weighted Average |
Natl: 90% |
Reg: 93% |
Natl: 90% |
Reg: 93% |
Redemption at Investor's Option
|
Yes |
Yes |
Natl: 59% |
Reg: 48% |
Natl: 59% |
Reg: 48% |
Pay-to-Play Penalties
|
|
|
| |
|
|
|
Cumulative Dividends
|
No |
No |
Natl: 64% |
Reg: 79% |
Natl: 64% |
Reg: 79% |
Reorganization or Recapitalization
|
No |
No |
Natl: 93% |
Reg: 96% |
Natl: 93% |
Reg: 96% |
Valuation Ticker
The Valuation Ticker is a venture capital valuation tracking tool that utilizes the average daily close prices of public companies in particular industries. Each of these companies received venture capital or private equity funding prior to their IPO.
Utilizing averages from 1999 to present, these daily figures are then applied to the most recent post-money valuation of a private, venture-backed company within the same industry, as calculated by VC Experts, to simulate the movement of that company's valuation on a daily basis.
Additional data is utilized as a comparative measure, including the NASDAQ and S&P 500 indexes. With this tool, VCs, hedge fund managers, investment bankers and other investor groups can create a bucket of comparable analysis, as well as determine potential entry points when to go public.
